- Home
- PCRX vs IOVA Comparison
PCRX vs IOVA Comparison
Compare PCRX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- IOVA
- Stock Information
- Founded
- PCRX 2006
- IOVA 2007
- Country
- PCRX United States
- IOVA United States
- Employees
- PCRX N/A
- IOVA N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- IOVA Health Care
- Exchange
- PCRX Nasdaq
- IOVA Nasdaq
- Market Cap
- PCRX 1.2B
- IOVA 1.0B
- IPO Year
- PCRX 2011
- IOVA N/A
- Fundamental
- Price
- PCRX $25.12
- IOVA $1.75
- Analyst Decision
- PCRX Buy
- IOVA Strong Buy
- Analyst Count
- PCRX 9
- IOVA 9
- Target Price
- PCRX $29.89
- IOVA $15.50
- AVG Volume (30 Days)
- PCRX 782.0K
- IOVA 14.9M
- Earning Date
- PCRX 05-08-2025
- IOVA 05-08-2025
- Dividend Yield
- PCRX N/A
- IOVA N/A
- EPS Growth
- PCRX N/A
- IOVA N/A
- EPS
- PCRX N/A
- IOVA N/A
- Revenue
- PCRX $702,772,000.00
- IOVA $212,679,000.00
- Revenue This Year
- PCRX $9.48
- IOVA $182.20
- Revenue Next Year
- PCRX $11.31
- IOVA $62.10
- P/E Ratio
- PCRX N/A
- IOVA N/A
- Revenue Growth
- PCRX 3.08
- IOVA 11070.12
- 52 Week Low
- PCRX $11.16
- IOVA $2.70
- 52 Week High
- PCRX $31.67
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- PCRX 48.10
- IOVA 23.78
- Support Level
- PCRX $25.08
- IOVA $3.02
- Resistance Level
- PCRX $27.34
- IOVA $3.31
- Average True Range (ATR)
- PCRX 1.16
- IOVA 0.24
- MACD
- PCRX -0.18
- IOVA -0.09
- Stochastic Oscillator
- PCRX 48.85
- IOVA 4.81
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.